Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial

计划入组 66 人 · 首次发布于 2026 年 7 月 20 日

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

计划入组 15 人 · 首次发布于 2018 年 7 月 23 日

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

计划入组 32 人 · 首次发布于 2018 年 5 月 31 日

TFEB

CTx-TFEB

MIPLYFFA Shows 5-Year Sustained Efficacy in Rare NPC Disease Extension Study

Zevra Therapeutics Launches MIPLYFFA, First FDA-Approved Treatment for Niemann-Pick Disease Type C

Zevra Therapeutics Expands Global Access to MIPLYFFA Through Distribution Partnership with Uniphar